BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gajewska M, Goryński P, Paradowska-Stankiewicz I, Lewtak K, Piotrowicz M, Urban E, Cianciara D, Wysocki MJ, Książek A, Izurieta P. Monitoring of community-acquired pneumonia hospitalisations before the introduction of pneumococcal conjugate vaccine into Polish National Immunisation Programme (2009-2016): A nationwide retrospective database analysis. Vaccine 2020;38:194-201. [PMID: 31653527 DOI: 10.1016/j.vaccine.2019.10.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Rejas J, Sicras-Mainar A, Sicras-Navarro A, Lwoff N, Méndez C. All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain. Expert Rev Pharmacoecon Outcomes Res 2021. [PMID: 34949148 DOI: 10.1080/14737167.2022.2020649] [Reference Citation Analysis]
2 Ben Fredj M, Dhouib W, Kacem M, Bennasrallah C, Mehrez O, Abroug H, Zemni I, Gardabou A, Jamel K, Chouchene S, Rouatbi N, Belguith Sriha A. Trends and health burden of hospitalized acute respiratory infections and impact of Haemophilus influenza immunization in a Tunisian university hospital: a twelve-year study. Libyan J Med 2020;15:1783048. [PMID: 32552441 DOI: 10.1080/19932820.2020.1783048] [Reference Citation Analysis]
3 Noguchi S, Yatera K, Muramatsu K, Fujino Y, Matsuda S, Mukae H. Mortality changes for patients with pneumococcal pneumonia from 2012 to 2017 in Japan. J Infect Chemother 2022:S1341-321X(22)00181-7. [PMID: 35718263 DOI: 10.1016/j.jiac.2022.06.006] [Reference Citation Analysis]
4 Malchrzak W, Mastalerz-Migas A. Epidemiologic Benefits of Pneumococcal Vaccine Introduction into Preventive Vaccination Programs. Adv Exp Med Biol 2021;1324:11-9. [PMID: 33136238 DOI: 10.1007/5584_2020_589] [Reference Citation Analysis]